Skip to main content
    B

    BridgeBio Pharma Inc (BBIO)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $77.36
    -0.94 (-1.20%)

    Market Cap: $15.25B

    Last updated: Nov 17, 2026 at 11:05 AM ET

    BridgeBio Pharma Inc (BBIO) Financials: Revenue, Profit and Cash Flow

    Updated Oct 29, 2026. Financial statements from company filings, amounts in US dollars.

    BridgeBio Pharma reported revenue of $502.08M for the fiscal year ended Dec 31, 2025, up 126.3% from the year before. That year, net income was -$732.94M with a net margin of -146.0%, operating cash flow was -$445.91M and free cash flow was -$447.01M. The quarter ended Sep 30, 2026 had revenue of $353.17M and net income of -$60.50M.

    Revenue and Margins

    Over the 6 years to Dec 2025, revenue grew from $40.56M, a compound annual rate of 52.1%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$502.08M+126.3%95.8%-104.2%-146.0%
    Dec 2024$221.90M+2285.3%98.3%-267.2%-244.9%
    Dec 2023$9.30M-88.0%73.7%-6528.8%-7021.9%
    Dec 2022$77.65M+11.4%95.6%-659.6%-624.2%
    Dec 2021$69.72M+745.1%95.5%-827.1%-841.2%
    Dec 2020$8.25M-79.7%100.0%-5752.0%-6127.9%
    Dec 2019$40.56MN/A100.0%-656.4%-711.5%
    Dec 2018$0N/AN/AN/AN/A
    Dec 2017$0N/AN/AN/AN/A
    Annual, fiscal years ended Dec 2017 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Sep 2026, the net loss narrowed from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017
    Revenue$502.08M$221.90M$9.30M$77.65M$69.72M$8.25M$40.56M$0$0
    Cost of revenue$20.96M$3.88M$2.45M$3.43M$3.11M$0$0$0$0
    Gross profit$481.11M$218.02M$6.86M$74.21M$66.60M$8.25M$40.56M$0$0
    Research and development$451.95M$506.46M$455.71M$399.46M$451.02M$337.05M$209.95M$140.07M$30.56M
    Operating income-$523.41M-$592.97M-$607.37M-$512.20M-$576.63M-$474.48M-$266.24M-$183.66M-$43.86M
    Net income-$732.94M-$543.35M-$653.25M-$484.65M-$586.45M-$505.49M-$288.58M-$169.45M-$43.83M
    EBITDA-$468.95M-$567.16M-$570.57M-$404.99M-$534.97M-$471.39MN/AN/A-$43.86M
    Fiscal years ended Dec 2017 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$353.17M$243.68M$194.51M$154.18M$120.70M$110.56M$116.63M$3.71M$2.73M$4.34M$211.12M$1.75M
    Gross profit$332.72M$228.63M$184.58M$146.07M$114.14M$106.91M$113.99M$2.23M$2.13M$3.14M$210.52M$1.15M
    Operating income-$11.64M-$107.08M-$105.96M-$139.56M-$145.20M-$134.28M-$104.37M-$226.03M-$191.75M-$175.54M$343.00K-$177.42M
    Net income-$60.50M-$155.89M-$166.56M-$194.63M-$184.94M-$183.76M-$169.61M-$267.39M-$164.25M-$75.54M-$36.16M-$170.33M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, total debt of $1.85B exceeded cash and equivalents by $1.28B. Shareholder equity was negative, at -$2.09B, as total liabilities of $3.01B exceeded total assets of $936.02M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017
    Total assets$936.02M$919.34M$546.38M$623.04M$1.01B$703.59M$631.68M$464.94M$98.04M
    Current assets$797.75M$720.69M$477.59M$548.85M$888.86M$642.82M$568.62M$445.22M$97.13M
    Cash and equivalents$570.12M$681.10M$375.94M$376.69M$393.77M$356.08M$363.77M$436.09M$92.00M
    Total liabilities$3.01B$2.38B$1.89B$1.87B$1.88B$595.70M$155.70M$87.58M$152.73M
    Short-term debt$0$4.51M$4.13M$3.67M$4.94M$1.46M$0N/AN/A
    Long-term debt$1.85B$1.72B$446.44M$430.99M$430.75M$92.42M$91.79M$54.51MN/A
    Shareholder equity-$2.09B-$1.47B-$1.35B-$1.25B-$870.41M$57.91M$408.45M$314.88M-$58.02M
    Fiscal years ended Dec 2017 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$2.16B$1.22B$1.37B$936.02M$998.25M$1.08B$881.64M$919.34M$664.98M$794.38M$849.33M$546.38M
    Total liabilities$3.82B$3.72B$3.64B$3.01B$2.92B$2.86B$2.52B$2.38B$1.88B$1.88B$1.89B$1.89B
    Cash and equivalents$1.53B$677.91M$879.89M$570.12M$642.95M$748.95M$540.60M$681.10M$266.32M$407.96M$475.22M$375.94M
    Shareholder equity-$1.66B-$2.52B-$2.28B-$2.08B-$1.93B-$1.79B-$1.65B-$1.47B-$1.23B-$1.09B-$1.05B-$1.35B
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017
    Operating cash flow-$445.91M-$520.73M-$527.72M-$419.49M-$497.93M-$399.71M-$253.59M-$136.64M-$40.49M
    Capital expenditures$1.10M$933.00K$1.31M$4.82M$13.25M$7.52M$2.64M$2.18M$464.00K
    Free cash flow-$447.01M-$521.66M-$529.03M-$424.31M-$511.18M-$407.23M-$256.23M-$138.82M-$40.95M
    Dividends paid$2.15M$0$801.00KN/A$3.82M$5.00M$55.01M$44.23M$1.15M
    Share repurchases$48.28M$0$0N/A$200.00M$75.00M$0$0$0
    Investing cash flow-$24.49M$60.78M$54.03M$453.15M-$200.83M-$52.99M-$217.25M-$21.04M-$464.00K
    Financing cash flow$359.29M$748.46M$451.54M-$13.13M$736.45M$447.19M$398.79M$501.55M$112.98M
    Fiscal years ended Dec 2017 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$44.17M-$71.10M-$197.28M-$56.42M-$109.57M-$80.68M-$199.24M-$195.33M-$180.57M$74.70M-$219.54M-$124.82M
    Capital expenditures$290.00K$443.00K$69.00K$33.00K$470.00K$594.00K$0$47.00K$137.00K$54.00K$695.00K$435.00K
    Free cash flow-$44.46M-$71.54M-$197.35M-$56.45M-$110.04M-$81.28M-$199.24M-$195.37M-$180.70M$74.65M-$220.23M-$125.25M
    Last 12 quarters

    Frequently Asked Questions About BBIO

    What is BridgeBio Pharma's annual revenue?

    BridgeBio Pharma reported revenue of $502.08M for the fiscal year ended Dec 31, 2025.

    How fast is BridgeBio Pharma's revenue growing?

    Revenue was up 126.3% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 86.3%.

    Is BridgeBio Pharma profitable?

    No. BridgeBio Pharma reported net income of -$732.94M for the fiscal year ended Dec 31, 2025, with a net margin of -146.0%.

    How much free cash flow does BBIO generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$445.91M minus capital expenditures of $1.10M produced free cash flow of -$447.01M.

    How much debt does BridgeBio Pharma have?

    The balance sheet dated Dec 31, 2025 reported long-term debt of $1.85B, short-term debt of $0 and cash and equivalents of $570.12M.